Cargando…

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies

Detalles Bibliográficos
Autores principales:	Bal, Susan, Estrada-Merly, Noel, Costa, Luciano J., Qazilbash, Muzaffar H., Kumar, Shaji, D’Souza, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651880/ https://www.ncbi.nlm.nih.gov/pubmed/37968258 http://dx.doi.org/10.1038/s41408-023-00945-0

Ejemplares similares

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2020)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma
por: Dalland, Joanna C., et al.
Publicado: (2021)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
por: Kansagra, Ankit, et al.
Publicado: (2022)

The t(11;14)(q13;q32)/CCND1–IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course
por: Liu, Ying, et al.
Publicado: (2019)

T cell acute lymphoblastic leukemia with t(11;14)(p13;q11) and trisomy 8
por: Safavi, Moeinadin, et al.
Publicado: (2021)

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
por: Nassereldine, Hasan, et al.
Publicado: (2022)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
por: Nakahara, Wataru, et al.
Publicado: (2023)

SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma
por: Wang, Yazhu, et al.
Publicado: (2022)

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

Persistence of a t(11;14)‐positive clone in a patient with mantle cell lymphoma for 20 years
por: Otsuka, Yasuyuki, et al.
Publicado: (2017)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

The chromosome translocation (11;14)(p13;q11) associated with T cell acute leukemia. Asymmetric diversification of the translocational junctions
Publicado: (1990)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

Recent advances in understanding and treating immunoglobulin light chain amyloidosis
por: Badar, Talha, et al.
Publicado: (2018)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Induction of t(11;14) IgH enhancer/promoter-cyclin D1 gene translocation using CRISPR/Cas9
por: Tsuyama, Naohiro, et al.
Publicado: (2019)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study
por: Ni, Ivyna Bong Pau, et al.
Publicado: (2012)

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
por: Weinhold, Niels, et al.
Publicado: (2013)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

11.14 The Role of Psychological Inflexibility in the Relationship Between Depression and Energy Levels Among Emerging Adults During the COVID-19 Pandemic
por: Ruiz, Elaine, et al.
Publicado: (2021)

P832: PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T(11;14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY
por: Gavriatopoulou, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5s6vse1biigeru02db1qbgcdo7